Naaju Breaking News, Live Updates, Latest Headlines, Viral News, Top Stories, Trending Topics, Videos
[ad_1]
The prestigious medical journal The Lancet published preliminary results of the phase III trial of the Russian vaccine Sputnik V against the coronavirus, which show that the antidote is more than 91% effective. We then compare this data and other key data about the drug with that of the three other vaccines whose Phase III clinical trial results have been published in the leading peer-reviewed medical journals: Pfizer, Moderna and AstraZeneca.
Efficiency
According to peer-reviewed Phase III articles, three of the four mentioned antidotes showed an overall efficacy of over 90%: Sputnik V (91.6%), Pfizer’s vaccine (95%), and Moderna’s vaccine (94 , 1%). During this time, the estimated effectiveness of the drug AstraZeneca is 62.1%.
In contrast, Sputnik V, Moderna and AstraZeneca are 100% effective against severe cases, compared to the Pfizer vaccine (75%).
Temperature regime
A key benefit of Sputnik V is the storage and transport temperature it requires, between 2 ° C and 8 ° C, while mRNA vaccines require much more extreme temperatures, between -70 and -20 degrees Celsius.
Specifically, Pfizer’s medicine can be stored between -80 C to -60 C, while Moderna’s can be stored between -25 C and -15 C. For AstraZeneca vaccine, the temperature is the same as you need. Sputnik V: between 2 C and 8 C.
Price
The Russian vaccine also stands out for its affordable price, less than $ 10 per injection, being two to three times cheaper than other vaccines with more than 90% effectiveness, according to the Russian Direct Investment Fund (RDIF). , who sponsored the development of the drug. Of the other three immunizers, only AstraZeneca costs less than $ 10 per dose, while the price of the antidote developed by Pfizer is $ 19.5 and that of Moderna is $ 37.
Also worth noting is the high safety of the Sputnik V vaccine, which has not been associated with serious side effects, significant allergies or anaphylactic shock. The Russian antidote is based on a proven and well-studied platform of human adenoviral vectors that cause colds and have been around for thousands of years. In addition, two different vectors in two separate injections elicit a longer lasting immune response against other vaccines that use the same delivery mechanism for both injections.
As for the other three vaccines tested, phase III clinical trials have shown their safety, although long-term safety will determine over time.
Rt, WhasingtonPost, Forbes, Bbc, The Lancet.
.
[ad_2]
Source link
